GLP-1s & Weight Loss
Tesofensine
← Back to Library
FDA safety flag Protocol not independently verified Metabolic Neural Thermogenic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Oral
Typical vial sizes: Not stated
Dosing window: Early Morning
Receptor / target: DAT; SERT; NET
Properties: Neural Stimulant
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 250mcg daily | Assess central nervous system tolerance. |
| Weeks 3-24 | 500mcg daily | Standard therapeutic dose. Do not exceed. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: EOD Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-24 | 250mcg Every Other Day (EOD) | Because the half-life is ~9 days, dosing EOD prevents excessive CNS accumulation and insomnia in sensitive researchers. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (DAT; SERT; NET); route Oral; timing Early Morning. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Clinical trial regimen(s): Original phase 2 obesity study tested daily oral tesofensine 0.25, 0.5, or 1.0 mg; PubMed records an expression of concern for that Lancet trial.
Independent safety notes: Independent review should flag the Lancet expression of concern and cardiovascular/psychiatric tolerability concerns reported in secondary literature.
Regulatory status: investigational not FDA approved
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Current or recent use of MAOIs (monoamine oxidase inhibitors): concurrent use risks life-threatening serotonin syndrome; require minimum 14-day washout after MAOI discontinuation before starting.
- Current use of SSRIs or SNRIs: additive serotonergic load significantly raises serotonin syndrome risk; coordinate carefully with prescribing physician.
- Current use of other stimulant compounds or sympathomimetics (amphetamines, phentermine, pseudoephedrine): additive cardiovascular and CNS stimulant effects.
- Uncontrolled hypertension: norepinephrine reuptake inhibition raises heart rate and may elevate blood pressure; baseline cardiovascular assessment recommended.
- Pre-existing cardiac arrhythmias or tachycardia: heart rate increases of 7.4 BPM at the 0.5mg dose were observed in Phase 2 data.
- History of anxiety disorders, panic disorder, or generalized anxiety disorder: norepinephrine/dopamine elevation significantly worsens anxiety and jitteriness.
- History of bipolar disorder or manic episodes: dopamine elevation may precipitate manic episodes.
- History of psychosis or schizophrenia spectrum disorders: dopaminergic potentiation may exacerbate psychotic symptoms.
- History of substance use disorder, particularly stimulant abuse: dopamine transporter inhibition creates some abuse potential in predisposed individuals.
- History of suicidal ideation: monitor closely; mood changes including depressed mood reported in Phase 2 data.
- Pregnancy: CNS stimulant activity; safety not established; avoid use.
- Breastfeeding: safety not established; avoid use.
- Known hypersensitivity to tesofensine or any formulation excipients.
- Severe hepatic impairment: metabolized hepatically; clearance impaired.
- Severe renal impairment: limited safety data.
- Concomitant use with triptans: serotonergic interaction risk.
- Concomitant use with tramadol or other serotonergic opioids: additive serotonin syndrome risk.
- Pediatric use: safety and efficacy not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Insomnia: most clinically problematic adverse effect; the ~9-day half-life means CNS stimulation is persistent; strict early morning dosing is mandatory to minimize this.
- Dry mouth: reported frequently across all dose levels in Phase 2 trials; driven by noradrenergic and cholinergic modulation.
- Elevated resting heart rate: mean increase of 7.4 BPM at 0.5mg dose in Phase 2 data; consistent across subjects; dose-dependent.
- Nausea: reported across dose groups; generally mild and transient.
- Constipation and hard stools: gastrointestinal motility effects of monoamine modulation.
- Diarrhea: paradoxically reported in some subjects alongside constipation; inconsistent GI motility effects.
- Anxiety and jitteriness: norepinephrine and dopamine elevation amplify anxiety in predisposed subjects.
- Elevated blood pressure: modest increases observed at higher doses; monitor in subjects with borderline hypertension.
- Headache: common during the early accumulation phase as CNS monoamine levels climb toward steady state.
- Depressed mood: observed in Phase 2 extension data; may reflect appetite satiety appetite center desensitization over time or dopamine dysregulation.
- Loss of appetite suppression over time: Phase 2 appetite data showed the composite satiety score diminished after week 12 despite continued weight loss; appetite suppression partially attenuates with sustained use.
- CNS accumulation effects from long half-life: gradual buildup over 4-6 weeks of daily dosing may produce intensifying side effects not apparent in the first 1-2 weeks.
- Flatulence: reported in Phase 2 data.
- Dizziness.
- Tremor or fine motor jitteriness: norepinephrine-mediated at higher doses.
- Reduced libido or sexual dysfunction: serotonergic effects comparable to SSRI class.
- Withdrawal effects upon cessation: due to long half-life, abrupt discontinuation may produce extended low-grade withdrawal: fatigue, mood changes, increased appetite; gradual tapering is recommended.
- Potential abuse liability in predisposed individuals: dopamine transporter inhibition; lower risk than classical stimulants but not zero in individuals with stimulant use history.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.